cbd 606December 15, 2021
The purpose of this notification is to invite Parties, Governments, international organizations, indigenous and local communities and relevant stakeholders to contribute to the preparatory work for the fourth meeting of the Ad Hoc Open-ended Working Group on Access and benefit-sharing and for the dissemination of information in accordance with the recommendations of the Working Group at its third meeting held in Bangkok, Thailand, in February 2005, and contained in the report of the meeting (document UNEP/CBD/WG-ABS/3/7).
Keywords: CBD; Cannabidiol; Cannabinoids; Cannabis sativa L.; GC/FID; Gas chromatography–flame ionization detection; Marijuana; Potency; Δ(9)-tetrahydrocannabinol.
This review examines the concentration of seven major cannabinoids, including Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), in illicit herbal cannabis products seized by the Drug Enforcement Administration (DEA) over the last 10 years in the United States. Cannabis samples received from DEA regional laboratories were analyzed by a validated gas chromatography with flame ionization detection method, and the results are given in the report. A total of 14,234 samples of herbal cannabis have been analyzed over the last 10 years (between January 1, 2009, and December 31, 2019). The number of samples received over the last 5 to 6 years has decreased dramatically owing to the legalization of marijuana for either medical or recreational purposes in many U.S. states. The results showed that the mean Δ 9 -THC concentration has increased over the last 10 years, from 9.75% in 2009 to 14.88% in 2018 and 13.88% in 2019. The mean Δ 9 -THC:CBD ratio rose substantially from 24.81 in 2009 to 103.48 in 2017. A decrease in THC:CBD ratio was recorded in the last 2 years, 54.39 in 2018 and 24.58 in 2019, indicating the trend in the production of more high-CBD-containing products. Our results showed an overall increase in potency of illicit cannabis, from approximately 10% in 2009 to approximately 14% in 2019. These results are in agreement with other potency monitoring programs in several European countries. There appears to be a recent trend of the inclusion of higher CBD levels containing chemovars in illicit cannabis.
Copyright © 2021 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
We use a broad array of cannabis products to address illnesses and injuries. Our team will guide you through your options to ensure you are comfortable with your treatment plan.
Our mission is to provide quality treatment with compassion and convenience. We offer a natural alternative method of healing without the use of industrialized pharmaceuticals.
Our goal is to provide our clients with the highest level of care and create a treatment plan that will best suit your needs.